As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on developing innovative antibody drugs to meet domestic and overseas patients’ needs. Since its establishment in October 2019, the company has built a product pipeline for more than 10 Biocytogen’s independently developed targets.
Eucure clinical development team is experience in developing drugs domestically and globally. The team’s function covers pharmacy (CMC), pharmacology and toxicology, regulatory affairs, clinical medicine, clinical operations, data management and statistical analysis, drug safety and pharmacovigilance. Our core competitiveness lies in the global strategic vision and international clinical development experience; the ability to design clinical study protocols for various types of clinical studies at various stages; the experience in international regulatory affairs (FDA, TGA and NMPA); efficient and powerful clinical operation execution and cooperation with KOL/PI.
In accordance with Biocytogen’s strategic planning, we are based in Beijing, Shanghai and the United States.